GlassScriptPhysician profile
Jose Kuzhively
NPI 1295090330
$7,133.77
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,346 · 2020: $502 · 2021: $1,152 · 2022: $1,494 · 2023: $618 · 2024: $21.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.06 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $1,379.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $814.86 | 2019-2023 | |
| Amgen INC. | $566.46 | 2019-2023 | Prolia, Evenity |
| Abbott Laboratories | $465.84 | 2020-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $454.11 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $426.94 | 2019-2022 | |
| Novo Nordisk INC | $325.02 | 2019-2022 | |
| Lilly USA, LLC | $277.41 | 2019-2021 | |
| Medtronic Minimed, INC. | $244.20 | 2019-2020 | |
| Insulet Corporation | $218.20 | 2019-2023 | Omnipod |
| Dexcom, INC. | $215.66 | 2021-2023 | Dexcom G6 Transmitter |
| Coloplast Corp | $155.02 | 2019 | |
| Horizon Therapeutics Plc | $136.42 | 2021-2022 | |
| Radius Health, INC. | $116.76 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.82 | 2022-2023 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Kuzhively listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.